Advertisement

Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.